card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Liquid Biopsy Collection in Clinical Development Programs

Home / Insights / Liquid Biopsy Collection in Clinical Development Programs

 

A liquid biopsy is a minimally invasive alternative to a more traditional surgical solid tumor biopsy.

 

In this episode, Dr. Stephanie Hastings lays out the considerations for liquid biopsy collection and the type of information that can be gathered from circulating free DNA (cfDNA).

 

The main approaches comprise for evaluating cfDNA are:

  1. specific mutation detection to help support targeted therapies
  2. broader sequencing technologies to enable biomarker evaluations
  3. custom sequencing panels to support clinical trial assay development

She describes the typical panels for each of the approaches, the sample collection requirements and how these analyses are implemented on a global scale.